Back to today’s briefing

Story perspectives

AstraZeneca Targets Lung Cancer: 50% Patient Reach by 2030

8/9/2025

27 3

Summary

Story summary

AstraZeneca is making strides in the fight against genetic lung cancer, specifically targeting EGFR mutations. With a bold goal to reach over half of lung cancer patients by 2030, they are combining innovative therapies and enhanced screening. Their flagship drug, Tagrisso, has already transformed treatment, marking a significant milestone in patient care.

1 of 1

Story summary

AstraZeneca is making strides in the fight against genetic lung cancer, specifically targeting EGFR mutations. With a bold goal to reach over half of lung cancer patients by 2030, they are combining innovative therapies and enhanced screening. Their flagship drug, Tagrisso, has already transformed treatment, marking a significant milestone in patient care.